Process for the preparation of Rivaroxaban involving novel intermediate
US 11,891,384 In forceTerm ends Mar 26, 2039 · From the USPTO record
20-year base term ends Dec 21, 2037
Dec 21, 2017
Mar 26, 2039
Feb 6, 2024
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 21, 2017, when the earliest non-provisional application in its chain was filed (this one was filed May 3, 2021); a parent in its chain could not be resolved (the next row) | Dec 21, 2037 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +460 days, USPTO patent term adjustment record | Mar 26, 2039 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 26, 2039 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.